Connect with us

Announcements

Flower One Opens Nevada’s Biggest Tech-Savvy Cannabis Extraction and Production Facility

Published

on

Flower One Opens Nevada's Biggest Tech-Savvy Cannabis Extraction and Production Facility

In a recent press release, Flower One Holdings, an innovative CBD company that cultivates and produces cannabis, is opening a Nevada facility through its subsidiary Canna Nevada Corp. The facility will features technology for the advanced production of cannabis in a lab, and it will also operate next to the company’s 400,000 square-foot greenhouse.

The new facility will feature 55,000 square feet, and it will be able to consume 3,000 to 5,000 biomass per week. The distillate processing will have an ethanol extraction method, with extraction ranging from 100 to 150 liters per week. The new facility, according to the press release, will enable the company to generate product “from its more than 140,000 pounds (62,500 kg) of dry cannabis flower and trim expected annually from the greenhouse.”

The company’s Director of Extraction and Production, Thomas Rosengen, stated in the press release,

“The Launch of Flower One’s bulk distillate process train has been a resounding success – with early lot potencies already testing in the 90%+ range.”

The company’s Chief Strategy Officer, Kellen O’Keefe, also stated in the press release,

“The product and test results coming out of the lab mark another huge milestone for Flower One and our ability to produce premium quality cannabis products. Flower One is thrilled to bring some of the nation’s leading cannabis brands to Nevada’s retailers and consumers.”

In addition, Flower One issued a Corporate Update, that included a planting update. In the announcement, the company indicated that it “hit an important milestone” due to the onboarding of plants into its greenhouse. It also achieved cultivation milestones, which are as follows:

“Two climate-controlled, spectrum adjustable cutting cells are in full operational mode and have rooted more than 100,000 cannabis cuttings (small plants). In the greenhouse, the Company has constructed three expansive, multi-density ebb and flood zones, which are now fully populated with plants. The greenhouse has been designed to have eight large “flower” zones. Once fully canopied, the greenhouse is expected to operate on a perpetual cycle of harvesting one zone per week (representing, on average, 10,000 plants per harvest). To date, we are 50% canopied, with four of the eight zones planted, amounting to 200,000 square feet of plants.”

In its press releases, the company recognizes, due to its association with cannabis, that its “activities are currently illegal under United States federal law.”

All information is for general informational and educational purposes only. Nothing should be interpreted as legal or wellness advice.

Jane is a regular contributor who learned about the great benefits of CBD a few years ago after starting it herself. Impressed by its effects, she's interested in helping others learn about options that can be helpful for them.

Continue Reading

Ultimate CBD Guide


Disclaimer

ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email contact@timesofcbd.com

Copyright © 2020 TimesofCBD.com | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.